Summary
This article discusses potential drug/disease interaction between the glucagon-like peptide-1 (GLP-1)-based diabetic therapies and pancreatitis (acute and chronic) and pancreatic cancer.
- Gastrointestinal Cancers
 - Diabetes Mellitus
 
- Gastrointestinal Cancers
 - Diabetes Mellitus
 - Endocrinology
 - Diabetes & Metabolic Syndrome
 
- © 2013 MD Conference Express®
 










